JanOne Inc.

Equities

JAN

US47089W1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
3.05 ^USD	-7.85%		-12.61%	+449.55%

May. 17	Exchange-Traded Funds, Equity Futures Tread Water Pre-Bell Friday Amid Waning September Rate Cut Hopes	MT
May. 16	JanOne Closes Acquisition of Blockchain Fintech Firm -- Shares Fall After Hours	MT

JanOne Inc. Appoints Tony Isaac as its Corporate Secretary

October 06, 2021 at 08:31 am EDT

JanOne Inc. announced that its board of directors appointed Tony Isaac, the company's current Chief Executive Officer, as the Companys Corporate Secretary. Mr. Isaac has been the company's Chief Executive Officer since May of 2016. Mr. Isaac will remain in such position.

Latest news about JanOne Inc.

Exchange-Traded Funds, Equity Futures Tread Water Pre-Bell Friday Amid Waning September Rate Cut Hopes	May. 17	MT
JanOne Closes Acquisition of Blockchain Fintech Firm -- Shares Fall After Hours	May. 16	MT
JanOne Inc. completed the acquisition of Alt 5 Sigma Inc.	May. 15	CI
JanOne to Acquire ALT 5 Sigma	May. 10	MT
JanOne Inc. executed a Definitive Agreement to acquire Alt 5 Sigma Inc.	May. 09	CI
JanOne Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024	May. 03	CI
JanOne Files Prospectus for $100 Million Mixed Shelf Offering	Apr. 18	MT
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
JanOne Inc. Reports Earnings Results for the Full Year Ended December 30, 2023	Apr. 08	CI
JanOne Inc. announced that it expects to receive $0.6 million in funding	Feb. 22	CI
JanOne Inc. announced that it expects to receive $0.3 million in funding from Live Ventures Incorporated	Feb. 06	CI
JanOne Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech	Nov. 09	MT
Investors Await Jobless Claims Report, Powell Speech as US Futures Remain Flat in Thursday Trading	Nov. 09	MT
Top Premarket Gainers	Nov. 09	MT
JanOne Raises $790,000 in Registered Direct Offering of Shares, Private Placement of Warrants	23-08-23	MT
JanOne Prices Registered Direct Offering, Announces Concurrent Private Placement	23-08-21	MT
JanOne Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 01, 2023	23-08-15	CI
Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain	23-06-28	CI
JanOne Inc. Reports Earnings Results for the First Quarter Ended April 01, 2023	23-05-22	CI
North American Morning Briefing : Debt-Ceiling -2-	23-05-17	DJ
JanOne Says Meeting With US FDA Provided Guidance for Regional Pain Syndrome Drug NDA	23-04-18	MT
JanOne Completes Pre-IND Meeting with FDA on Jan123	23-04-18	CI
JanOne Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
JanOne Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI

Chart JanOne Inc.

Duration

Period

More charts

Company Profile

JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. Its drug candidate is a treatment for Peripheral Artery Disease. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Company is also engaged in providing blockchain-powered technologies through its two platforms: ALT 5 Pay and ALT 5 Prime.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
JANONE INC.	+449.55%	27.62M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+45.49%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research